Pentostatin
Nipent (pentostatin) is a small molecule pharmaceutical. Pentostatin was first approved as Nipent on 1991-10-11. It is used to treat hairy cell leukemia in the USA. The pharmaceutical is active against adenosine deaminase.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Nipent (generic drugs available since 2007-08-07)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pentostatin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NIPENT | Hospira | N-020122 RX | 1991-10-11 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nipent | New Drug Application | 2020-10-14 |
| pentostatin | ANDA | 2022-11-07 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9268 | Injection, pentostatin, 10 mg |
Clinical
Clinical Trials
9 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Herpes labialis | D006560 | EFO_1001347 | B00.1 | — | — | 1 | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory tract infections | D012141 | J06.9 | — | — | 1 | — | — | 1 | |
| Rhinorrhea | D000086722 | — | — | 1 | — | — | 1 | ||
| Sneezing | D012912 | R06.7 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | 1 | — | — | 2 | 3 |
| Blood pressure | D001794 | EFO_0004325 | 1 | 1 | — | — | — | 1 | |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | 1 | 1 | — | — | — | 1 |
| Heart rate | D006339 | EFO_0004326 | 1 | 1 | — | — | — | 1 | |
| Rem sleep behavior disorder | D020187 | EFO_0007462 | G47.52 | 1 | 1 | — | — | — | 1 |
| Healthy volunteers/patients | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PENTOSTATIN |
| INN | pentostatin |
| Description | Pentostatin (or deoxycoformycin, trade name Nipent, manufactured by SuperGen) is an anticancer chemotherapeutic drug.
|
| Classification | Small molecule |
| Drug class | enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O |
Identifiers
| PDB | 1A4L |
| CAS-ID | 53910-25-1 |
| RxCUI | 8011 |
| ChEMBL ID | CHEMBL1580 |
| ChEBI ID | — |
| PubChem CID | 439693 |
| DrugBank | DB00552 |
| UNII ID | 395575MZO7 (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,652 documents
View more details
Safety
Black-box Warning
Black-box warning for: Nipent, Pentostatin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
77 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more